Versartis rakes in $55 mln in Series E funds
Versartis has closed $55 million in Series E financing. The investors include return backers Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency.
19 February 2014•2 mins read
